Show simple item record

dc.contributor.authorSugg, HVR
dc.contributor.authorFrost, J
dc.contributor.authorRichards, D
dc.date.accessioned2019-05-30T13:11:46Z
dc.date.issued2019-05-29
dc.description.abstractObjective To explore the views of UK-based recipients of Morita Therapy (MT) on the acceptability of MT. Design Qualitative study nested within a pilot randomised controlled trial of MT (a Japanese psychological therapy largely unknown in the UK) versus treatment as usual, using post-treatment semistructured interviews analysed with a framework approach. Setting and participants Participants who received MT as part of the Morita Trial, recruited for the trial from General Practice record searches in Devon, UK. Data from 16 participants were purposively sampled for analysis. Results We identified five themes which, together, form a model of how different participants viewed and experienced MT. Overall, MT was perceived as acceptable by many participants who emphasised the value of the approach, often in comparison to other treatments they had tried. These participants highlighted how accepting and allowing difficulties as natural phenomena and shifting attention from symptoms to external factors had facilitated symptom reduction and a sense of empowerment. We found that how participants understood and related to the principles of MT, in light of their expectations of treatment, was significantly tied to the extent to which MT was perceived as acceptable. Our findings also highlighted the distinction between MT in principle and practice, with participants noting challenges of engaging with the process of therapy such as fear and discomfort around rest, needing sufficient support from the therapist and others, and the commitment of treatment. Conclusions People in the UK can accept the premise of MT, and consider the approach beneficial and novel. Therefore, proceeding to a large-scale trial of MT is appropriate with minor modifications to our clinical protocol. Participants’ expectations and understandings of treatment play a key role in acceptability, and future research may investigate these potential moderators of acceptability in MT.en_GB
dc.description.sponsorshipUniversity of Exeteren_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)en_GB
dc.identifier.citationVol. 9, article e023873en_GB
dc.identifier.doi10.1136/bmjopen-2018-023873
dc.identifier.urihttp://hdl.handle.net/10871/37306
dc.language.isoenen_GB
dc.publisherBMJ Publishing Groupen_GB
dc.rights© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.en_GB
dc.titleMorita Therapy for depression (Morita Trial): an embedded qualitative study of acceptabilityen_GB
dc.typeArticleen_GB
dc.date.available2019-05-30T13:11:46Z
dc.identifier.issn2044-6055
dc.descriptionThis is the final version. Available on open access from BMJ Publishing Group via the DOI in this recorden_GB
dc.descriptionData sharing statement: The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.en_GB
dc.identifier.journalBMJ Openen_GB
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en_GB
dcterms.dateAccepted2019-03-21
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2019-05-30
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2019-05-30T09:20:24Z
refterms.versionFCDAM
refterms.dateFOA2019-05-30T13:11:52Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Except where otherwise noted, this item's licence is described as © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.